Alerts

the market, decoded and noise-stripped

The whole-market feed is a paid feature — unlock it with any plan or credits.

Last 7 days’s filings

—

— critical— high

Signal vs noise

—

primary— procedural hidden

Biggest reactions · 1D

Loading…—

—

Importance

Reaction · 5mMoved ≥

CategoryIndustrySignals

Most recent first

INTEGRATED PROBSEINTEGRATED PROTEINS LTD.Procedural1m

Trading Window Closed from October 1 for Q2 Results

Integrated Proteins has closed its trading window from October 1, 2026 until 48 hours after the board meeting to approve unaudited Q2 results (quarter ended September 30, 2026). Promoters, directors, KMP, designated persons, employees and their immediate relatives cannot trade in company securities during this period. The board meeting date will be announced later. This is a routine SEBI compliance step before quarterly results.

Compliance Filing Details →

5m move—no reaction

OMKAR OVERSEASBSEOMKAR OVERSEAS LTD.Procedural2m

AGM voting results: 2 resolutions passed with over 99 percent approval

Omkar Overseas Ltd held its 30th AGM on September 26, 2026. Two ordinary resolutions were passed with over 99 percent votes in favor. Resolution 1 approved FY26 financial statements; Resolution 2 re-appointed Mrs. Parul Joshi as director. Out of 2,608 shareholders, only 18 attended in person. Turnout was low at 14.57 percent of 50 lakh outstanding shares. Promoter group holds zero shares in the company.

Compliance Filing Details →

5m move—reaction pending

VIVIMEDLABBSEVIVIMED LABS LIMITED3m

8th Committee of Creditors meeting scheduled for Sept 29, 2026

Vivimed Labs is under Corporate Insolvency Resolution Process following an NCLT order dated April 15, 2026. The 8th meeting of the Committee of Creditors is scheduled for September 29, 2026 via video conferencing, per IBBI insolvency rules. An Interim Resolution Professional is managing the process.

Nclt Insolvency AdmittedRegulatory & LegalChemicals - Speciality Filing Details →

5m move—reaction pending

Ganga PharmaceBSEGanga Pharmaceuticals Limited6m

Re-appointment of Managing Director Mr. Bharat Brijmohan Sharma

Mr. Bharat Brijmohan Sharma (DIN: 00077026) has been re-appointed as Managing Director of Ganga Pharmaceuticals for a further 3 years, effective April 01, 2026. Shareholders approved the move at the 37th AGM on September 26, 2026. He is not liable to retire by rotation and has not been debarred by SEBI. Sharma has 35 plus years of pharma industry experience. His spouse Mrs. Srijna Sharma is already a Whole-time Director on the board.

Management Changes Filing Details →

5m move—reaction pending

Umiya Mobile LBSEUmiya Mobile LimitedProcedural7m

14th AGM results: all 3 resolutions passed with 100 percent votes in favour

Umiya Mobile Limited held its 14th AGM on September 26, 2026 via video conferencing. All 3 ordinary resolutions passed with 100 percent votes in favour. Resolution 1: adoption of audited standalone financial statements for FY ended March 31, 2026. Resolution 2: re-appointment of Mr Girishkumar Premjibhai Jadvani (DIN 06452836) as Whole Time Director, retiring by rotation. Resolution 3: appointment of M/s HAY and Associates LLP as Statutory Auditors. 24 members cast 1,05,70,100 valid votes via remote e-voting; zero votes against and zero invalid votes. Promoters contributed 1,04,94,000 shares.

Compliance Filing Details →

5m move—reaction pending

TGLNSETEERTH GOPICON LIMITEDProcedural8m

Trading window closure until Q2 results; firm under insolvency process

Teerth Gopicon (TGL) is undergoing Corporate Insolvency Resolution Process after NCLT Ahmedabad admitted it on August 10, 2026. Mr. Ajit Gyanchand Jain has been appointed Interim Resolution Professional and board powers are suspended. The trading window for designated persons is closed from October 1, 2026, until 48 hours after unaudited Q2 and half year financial results for September 30, 2026, are declared. The result declaration date will be communicated later.

Compliance Filing Details →

5m move—reaction pending

Ganga PharmaceBSEGanga Pharmaceuticals Limited8m

37th AGM: 3 resolutions passed unanimously; MD re-appointed

Ganga Pharmaceuticals held its 37th AGM on September 26, 2026, concluding in 25 minutes. All 3 ordinary resolutions passed with 100 percent votes in favour and zero against. These were: adoption of audited financial statements for FY ended March 31, 2026; re-appointment of Mr Sanjay Kulkarni as Director (retiring by rotation); and re-appointment of Mr Bharat Brijmohan Sharma as Managing Director and CEO. Of 364 shareholders on record, 14 voted covering 54.16 percent of outstanding shares. Promoters polled 100 percent of holdings; public participation was 6.62 percent.

Board & Shareholder Meetings Filing Details →

5m move—reaction pending

GSSBSEGSS INFOTECH LIMITED10m

GSS Infotech AGM 2026: All 4 resolutions passed with over 98% majority

GSS Infotech held its 23rd AGM on Sept 25, 2026 via video conferencing. All 4 resolutions passed. Key items: adoption of FY26 audited standalone and consolidated financials (99.66% in favor), re-appointment of Mr. Rambabu Sampangi Kaipa as Director (99.64%), appointment of Mr. Bhargav Marepally as Managing Director for 5 years (98.83%), and regularization of Mr. Chaitanya Challa as Independent Director for 5 years (99.64%). Total 47.26 lakh shares were cast. Promoters did not vote on the MD appointment due to interest.

Board & Shareholder MeetingsComputers - Software Filing Details →

5m move—reaction pending

AARTIDRUGSBSEAARTI DRUGS LTD.10m

Aarti Drugs: Adhish Patil (promoter son) named MD; board changes

At the 41st AGM on Sept 26, 2026, shareholders approved several board changes. WTD Uday Patil retired by rotation and was replaced by Nilesh Patil. Adhish P. Patil, son of CMD Prakash Patil and former CFO since 2014, appointed as Managing Director effective Oct 1, 2026, as part of an orderly leadership transition. Three Independent Directors re-appointed for second 5-year terms from March 29, 2027. Joint MD Harshit Savla and WTD Harit Shah also re-appointed for 5 years from June 1, 2027.

Promoter Family Board EntryManagement ChangesPharmaceuticals Filing Details →

5m move—reaction pending

Get a live, personalized feed of market-moving filings — filter it, save views, and have it pushed to you.